Pulmotect careers

Founded in 2007, Pulmotect, Inc. is a clinical stage biotechnology company developing and commercializing an inhalant designed to prevent respiratory infections. The company’s blockbuster product is PUL-042, an inhaled therapeutic which aims to activate the body’s innate immune system resulting in highly-targeted lung protection against all major classes of pathogens, including pneumonia, influenza, and bioterror agents such as anthrax. Pulmotect is the recipient of multiple early stage investments and grants, as well as recognition and awards from the biotechnology community.